1. Loaded Anti-Human VEGFR2 mAb-Fc on Protein A Biosensor, can bind Biotinylated Human VEGFR2-6His-Avi with an affinity constant of 1.1 pM as determined in BLI assay. (Regularly tested) 2. Immobilized Biotinylated Human VEGFR2-His-Avi at 1μg/ml (100 μl/well)can bind Anti-Human VEGFR2 mAb. The ED50 of Anti-Human VEGFR2 mAb is 44.08 ng/ml. (Regularly tested)

VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 120-150 KDa and the accession number is P35968.

Human

HEK293 Cells

Protein-tyrosine kinase receptor flk-1,KDR,Kinase insert domain receptor,FLK-1,VEGFR-2,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1

Ala20-Glu764

Ala20-Glu764

Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Human Vascular endothelial growth factor receptor 2(KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo.The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.